Tenet (THC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Tenet Healthcare (THC) reported Q3 2025 revenue of $5.29 billion and EPS of $3.70, both surpassing analyst consensus estimates by 1.02% and 11.11% respectively. While adjusted admissions fell short of expectations, the company exceeded estimates for net patient service revenue per adjusted admission, overall net operating revenues, and adjusted EBITDA across both its Ambulatory Care and Hospital Operations segments. The stock has outperformed the broader market, returning +7.4% over the past month compared to the S&P 500's +3.6%.

Analysis

Tenet Healthcare (THC) reported strong Q3 2025 financial results, with revenue reaching $5.29 billion, a 3.3% year-over-year increase, surpassing the Zacks Consensus Estimate of $5.24 billion by 1.02%. Earnings Per Share (EPS) significantly outperformed, coming in at $3.70 against an estimate of $3.33, marking an 11.11% positive surprise and a substantial rise from $2.93 in the prior year.

While adjusted admissions and same-hospital admissions slightly missed analyst estimates, net patient service revenue per adjusted admission exceeded expectations at $16,068 versus $15,358.90. This suggests strong pricing power or an advantageous case mix. Both Ambulatory Care and Hospital Operations segments demonstrated solid performance, with Ambulatory Care net operating revenues growing 11.9% year-over-year to $1.28 billion and Hospital Operations and Services revenues increasing 0.8% to $4.01 billion, both beating estimates. Adjusted EBITDA for both segments also surpassed forecasts.

The company's stock has reflected this positive performance, returning +7.4% over the past month, outperforming the S&P 500's +3.6% change. Despite the strong earnings beat and market outperformance, Tenet currently holds a Zacks Rank #3 (Hold), indicating an expectation for its near-term performance to align with the broader market.

Key Decisions for Investors

• Monitor future admission trends to assess the sustainability of strong revenue per adjusted admission, given the Q3 volume miss.
• Evaluate the company's ability to maintain pricing power and operational efficiency in its Ambulatory Care and Hospital Operations segments, which were key drivers of the Q3 earnings beat.
• Consider the implications of the Zacks Rank #3 (Hold) in conjunction with recent stock outperformance when assessing near-term portfolio allocation.